Canaccord Genuity Group Trims Health Catalyst (NASDAQ:HCAT) Target Price to $11.00

Health Catalyst (NASDAQ:HCAT – Free Report) had its target price lowered by Canaccord Genuity Group from $12.00 to $11.00 in a report issued on Friday morning, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. Several other brokerages have also weighed in on HCAT. Stifel Nicolaus dropped their price objective on […]

Related Keywords

United States ,Canada ,Piper Sandler ,Stifel Nicolaus ,Linda Llewelyn ,Impax Asset Management Group ,Vanguard Group Inc ,Analyst Recommendations For Health Catalyst ,Canaccord Genuity Group ,Health Catalyst Inc ,Health Catalyst ,Royal Bank ,Clearbridge Investments ,Health Catalyst Company Profile ,Health Catalyst Stock Performance ,Hedge Funds Weigh In On Health Catalyst ,Barclays ,Dimensional Fund Advisors ,News Ratings For Health Catalyst Daily ,Securities Exchange Commission ,Free Report ,Genuity Group ,Moderate Buy ,Exchange Commission ,Asset Management Group ,Fund Advisors ,Get Free Report ,Health Catalyst Daily ,Nasdaq Hcat ,Thcat ,Medical ,Lower Price Target ,Canaccord Genuity Group Inc ,